1.Baffy, G. (2015). MicroRNAs in nonalcoholic fatty liver disease. Journal of clinical medicine, 4(12), 1977-1988.2.Ezaz, G., Trivedi, H. D., Connelly, M. A., Filozof, C., Howard, K., L. Parrish, M., ... & Lai, M. (2020). Differential associations of circulating MicroRNAs with pathogenic factors in NAFLD. Hepatology communications, 4(5), 670-680.3.Guo-yi Wu, Chen Rui, Ji-qiao Chen, Eiketsu Sho, Shan-shan Zhan, Xian-wen Yuan, Yi-tao Ding; MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1. Cellular Physiology and Biochemistry 18 December 2017; 44 (4): 1651–1664. https://doi.org/10.1159/0004857654.Guo, X., Peng, Z., He, Y., Fang, H., & Jiang, N. (2024). MiRNA-122 contributes to the effect of exercise on non-alcoholic fatty liver. Chinese Journal of Tissue Engineering Research, 28(2), 272.5.Hegazy,M. A., Abd ALgwad, I., Abuel Fadl, S., Sayed Hassan, M., Ahmed Rashed, L., & Hussein, M. A. (2021). Serum micro-rna-122 level as a simple noninvasive marker of mafld severity. Diabetes, Metabolic Syndrome and Obesity, 2247-2254.6.Hu, Y., Peng, X., Du, G., Zhang, Z., Zhai, Y., Xiong, X., & Luo, X. (2022). MicroRNA-122-5p inhibition improves inflammation and oxidative stress damage in dietary-induced non-alcoholic fatty liver disease through targeting FOXO3. Frontiers in Physiology, 13, 803445.7.Kan Changez, M. I., Mubeen, M., Zehra, M., Samnani, I., Abdul Rasool, A., Mohan, A., ... & Kumar, V. (2023). Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review. Journal of International Medical Research, 51(9), 03000605231197058.8.Li, Y. Y., Cao, C. Y., Zhou, Y. L., Nie, Y. Q., Cao, J., & Zhou, Y. J. (2020). The roles and interaction of FXR and PPARs in the pathogenesis of nonalcoholic fatty liver disease. Arab Journal of Gastroenterology, 21(3), 162-168.9.https://doi.org/10.1016/j.ajg.2020.04.01810.Musa, N. I., Agwa, S. H., Faheem, H. A., & Gharib Alam El-din, A. M. (2021). Evaluation of MicroRNA-122 as A Non-invasive Diagnostic Biomarker For Non-Alcoholic Fatty Liver Disease and NASH related Cirrhosis. QJM: An International Journal of Medicine, 114.11.Nakamura, M. T., Yudell, B. E., & Loor, J. J. (2014). Regulation of energy metabolism by long-chain fatty acids. Progress in lipid research, 53, 124-144.12.https://doi.org/10.1016/j.plipres.2013.12.00113.Salvoza, N. C., Klinzing, D. C., Gopez-Cervantes, J., & Baclig, M. O. (2016). Association of circulating serum miR-34a and miR-122 with dyslipidemia among patients with non-alcoholic fatty liver disease. PloS one, 11(4), e0153497.14.Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore, Md.), 77(4), 1335–1347. https://doi.org/10.1097/HEP.0000000000000004